⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872370 | 1.00 | — | — | |
| SCHEMBL975303 | 0.81 | — | — | |
| SCHEMBL6567371 | 0.79 | — | — | |
| SCHEMBL974504 | 0.73 | — | — | |
| SCHEMBL3898003 | 0.69 | — | — | |
| SCHEMBL2127024 | 0.69 | — | — | |
| SCHEMBL9958468 | 0.69 | — | — | |
| SCHEMBL9957680 | 0.69 | ALDH1A1 (0.39) | — | |
| SCHEMBL76137 | 0.65 | — | — | |
| SCHEMBL57118 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112437772-B | Bcl-2 inhibitors | 百济神州有限公司 | 2023-11-21 | — | — | CN | claimed |
| CN-116802179-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-09-22 | — | — | CN | claimed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | claimed |
| EP-4136084-A1 | BCL-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-02-22 | — | — | EP | claimed |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-01-05 | — | — | US | claimed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | claimed |
| CN-114929689-A | Bcl-2 inhibitors | 百济神州有限公司 | 2022-08-19 | — | — | CN | claimed |
| WO-2021208963-A1 | BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-10-21 | — | — | WO | claimed |
| WO-2021083135-A1 | Bcl-2 INHIBITORS | BEIGENE, LTD. (KY) | 2021-05-06 | — | — | WO | claimed |
| EP-3788042-A1 | BCL-2 INHIBITORS | BeiGene, Ltd. (KY) | 2021-03-10 | — | — | EP | claimed |
| EP-1082322-B1 | OXAZOLIDINONE DERIVATIVES AS ANTIBIOTIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2004-01-28 | — | — | EP | claimed |
| EP-1357122-A2 | Oxazolidinone compounds and pharmaceutical compositions containing them | AstraZeneca AB (SE) | 2003-10-29 | — | — | EP | claimed |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | claimed |
| EP-0892799-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-08-22 | — | — | EP | claimed |
| EP-0892799-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1999-01-27 | — | — | EP | claimed |
| US-H1759-H | NEW HERBICIDE MOLECULAR COMPRISING A RING SELECT FROM THE GROUP OF PYRIMIDINE, TRIAZOLE, PYRAZOLE, ISOINDOLE, THIADIAZOLO(3,4-A)PYRIDAZINE, TRIAZINE(1,2,4), INDAZOLE, TETRAZOLE, TRIAZOLE(4,3-A)PYRIDINE | FMC CORPORATION (US) | 1998-11-03 | — | — | US | claimed |
| US-5770603-A | ANTICARCINOGENIC AGENTS | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | claimed |
| WO-1997038994-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-10-23 | — | — | WO | claimed |
| WO-1997032879-A1 | 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| US-5658942-A | Octahydronaphthalene oxime compounds for cholesterol synthesis inhibition | SANKYO COMPANY, LIMITED (JP) | 1997-08-19 | — | — | US | claimed |